Who
Jason Cavalier
Principal Financial Officer
Company insider
Files Form 4 as: Principal Financial Officer, Lyra Therapeutics.
In numbers
- Trades disclosed
- 11
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $11K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 13 Sep 2021
- Last trade
- 1 Apr 2026
- Last filed
- 3 Apr 2026
Companies traded
Activity over time
1 Jul 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Apr 2026filed 3 Apr 2026 | Lyra TherapeuticsMedical Devices | SEC FORM 4 Code D | —667 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | Lyra Therapeutics | SEC FORM 4 Code D | —667 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | Lyra TherapeuticsMedical Devices | SEC FORM 4 Sold | $2,587769 at $3.36 | filing |
| 6 Jan 2026filed 8 Jan 2026 | Lyra Therapeutics | SEC FORM 4 Sold | $2,584769 at $3.36 | filing |
| 10 Jul 2025filed 14 Jul 2025 | Lyra Therapeutics | SEC FORM 4 Sold | $6,094684 at $8.91 | filing |
| 8 Jan 2025filed 10 Jan 2025 | Lyra Therapeutics | SEC FORM 4 Code A | —420,000 at $0.00 | filing |
| 16 Oct 2024filed 18 Oct 2024 | Lyra Therapeutics | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 30 Jan 2024filed 1 Feb 2024 | Lyra Therapeuticsoption or derivative | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 31 Jan 2023filed 2 Feb 2023 | Lyra Therapeuticsoption or derivative | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 12 Feb 2022filed 15 Feb 2022 | Lyra Therapeuticsoption or derivative | SEC FORM 4 Code A | —15,605 at $0.00 | filing |
| 13 Sep 2021filed 15 Sep 2021 | Lyra Therapeuticsoption or derivative | SEC FORM 4 Code A | —104,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.